MyFinsight
Home
Blog
About
Trade receivables
-$4,554K
(-794.21%↓ Y/Y)
Inventories
-$3,376K
(-164.75%↓ Y/Y)
Share-based compensation
expense
$1,723K
(-32.77%↓ Y/Y)
Net income
$963K
(-88.90%↓ Y/Y)
Noncash lease expense
$179K
(-46.08%↓ Y/Y)
Amortization of intangibles
$174K
(132.00%↑ Y/Y)
Depreciation of leasehold
improvements and equipment
$117K
(-62.97%↓ Y/Y)
Interest accretion on
deferred consideration
$115K
Loss on disposal of
leasehold improvements...
-$23K
(-475.00%↓ Y/Y)
Non-cash financing costs
-$13K
(50.00%↑ Y/Y)
Gain on sale of
operating segment
-$3K
Deferred consideration
liability
$1K
Net cash provided by
operating activities
$2,772K
(-69.65%↓ Y/Y)
Canceled cashflow
$8,469K
Net increase in cash
and cash...
$191K
(-98.79%↓ Y/Y)
Canceled cashflow
$2,581K
Accounts payable
-$3,838K
(-174.47%↓ Y/Y)
Accrued expenses
-$3,780K
(-766.97%↓ Y/Y)
Prepaid expenses and
other assets
$350K
(221.53%↑ Y/Y)
Operating lease
liabilities
-$247K
(48.54%↑ Y/Y)
Deferred revenue
-$138K
(-245.26%↓ Y/Y)
Allowance for (recovery
of) credit losses
-$66K
(94.64%↑ Y/Y)
Customer deposits and
other
-$50K
(83.77%↑ Y/Y)
Proceeds from exercise of
stock options
$206K
(-97.00%↓ Y/Y)
Proceeds from issuance of
common stock from espp
$72K
Net cash (used in) /
provided by financing...
-$2,489K
(-136.35%↓ Y/Y)
Net cash provided by
/ (used in)...
-$92K
(44.91%↑ Y/Y)
Canceled cashflow
$278K
Repurchase of common stock
$2,767K
Purchases of leasehold
improvements and equipment
$89K
(-46.71%↓ Y/Y)
Transaction costs from sale
of operating...
$3K
Back
Back
Cash Flow
Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. (NAGE)
source: myfinsight.com